<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-ZBBURBU4/cf4f7f5c-4995-42cb-9112-d306c238b4bc/PDF"><dcterms:extent>1035 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-ZBBURBU4/c847d36b-5982-4d98-a4b2-06e171b46b32/TEXT"><dcterms:extent>0 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-ZBBURBU4"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2021</dcterms:issued><dc:creator>Frlan, Rok</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:72</dc:format><dc:format xml:lang="sl">str. 107-114</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:64803587</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-ZBBURBU4</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">Antibiotiki</dc:subject><dc:subject xml:lang="sl">nova indikacija starega zdravila</dc:subject><dc:subject xml:lang="sl">odpornost</dc:subject><dc:subject xml:lang="sl">preizkušanje učinkovin</dc:subject><dc:subject xml:lang="sl">protimikrobna zdravila</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Od starega zdravila do nove protimikrobne indikacije| Repurposing old drugs for new antimicrobial indication|</dc:title><dc:description xml:lang="sl">Antimicrobial resistance is one of the greatest threats to global public health today. A possible therapeutic strategy in the fight against microorganisms is to find new uses for approved or investigational drugs that are outside the scope of their original medical indication. Drug repurposing is a much cheaper and shorter alternative as compared to the typical route for de novo drug development. Despite many major advantages of drug repurposing, there are only a few success stories in the field of antimicrobials. A possible reason for that may lay in high prices of clinical trials, intellectual property laws, and the establishment of adequate pharmacokinetic and pharmacodynamic properties. In general, there are three basic methods that are used in drug repurposing research, phenotypic screening, computer-based methods and serendipitous observations. Because of the increased interest in drug repurposing, a significant increase of new antimicrobial drugs can be expected in the future</dc:description><dc:description xml:lang="sl">Povečevanje odpornosti mikroorganizmov na obstoječe terapevtske možnosti predstavlja resno grožnjo javnemu zdravju. Ena od strategij v boju proti mikroorganizmom je uporaba zdravil, ki prvotno niso bila namenjena terapiji okužb z mikrobi. Postopek razvoja, pri katerem staro zdravilo pridobi novo indikacijo, je bistveno cenejši in krajši kot razvoj popolnoma novega zdravila. Kljub mnogim prednostim je uspešnih zgodb na tem področju relativno malo. Vzrok so težave, ki so povezane s ceno kliničnih preskušanj, varstvom intelektualnih pravic in z zagotavljanjem ustreznih farmakokinetičnih ter farmakodinamičnih lastnosti preskušanih zdravil. Za raziskovanje protimikrobnih učinkov so v uporabi tri osnovne metode: fenotipsko rešetanje, računalniške metode ali naključno opazovanje neželenih učinkov. Glede na povečano zanimanje za to področje v zadnjih letih pričakujemo, da bo opisani pristop bistveno povečal nabor protimikrobnih zdravil v prihodnjih letih</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-ZBBURBU4"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-ZBBURBU4" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-ZBBURBU4/cf4f7f5c-4995-42cb-9112-d306c238b4bc/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-ZBBURBU4/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-ZBBURBU4" /></ore:Aggregation></rdf:RDF>